Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE D SHER

Allopathic & Osteopathic Physicians Pediatrics

NPI
1912923913
CMS profile
86506
Location
ROLLING HILLS ESTATES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$37,213.58

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE D SHER

NPI 1912923913 · CMS profile ID 86506

Allopathic & Osteopathic Physicians / Pediatrics

ROLLING HILLS ESTATES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $37,213.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $21.8202/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998967879 CMS
Regeneron Healthcare Solutions, Inc. $1.5301/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999438443 CMS
Regeneron Healthcare Solutions, Inc. $0.8401/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999438449 CMS
Regeneron Healthcare Solutions, Inc. $2.3201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999438455 CMS
AbbVie Inc. $22.1301/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998967871 CMS
AbbVie Inc. $2.5201/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998967875 CMS
AstraZeneca Pharmaceuticals LP $23.8501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015167605 CMS
Regeneron Healthcare Solutions, Inc. $30.9501/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999438437 CMS
AbbVie Inc. $28.0501/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998967867 CMS
AbbVie Inc. $5.8301/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998967863 CMS
Kowa Pharmaceuticals America, Inc. $14.1901/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003845847 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $103,218.50 126
PY2020 $49,747.75 74
PY2021 $34,420.00 91
PY2022 $28,760.12 88
PY2023 $37,213.58 111
PY2024 $20,982.33 62
PY2025 $22,334.03 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,061,303.99 321
PY2024 Recipient $29,331.55 17
PY2024 Principal investigator $7,111,011.48 216
PY2023 Recipient $14,443.64 20
PY2023 Principal investigator $7,232,124.60 4,231
PY2022 Recipient $108,639.12 16
PY2022 Principal investigator $7,703,527.25 144
PY2021 Recipient $133,070.70 39
PY2021 Principal investigator $6,913,610.43 156
PY2020 Recipient $519,510.56 81
PY2020 Principal investigator $1,777,135.06 125
PY2019 Recipient $329,908.59 150
PY2019 Principal investigator $1,346,770.32 191

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

321 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $5,594.40 12/19/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120958
Principal investigator 1 ModernaTX, Inc. $297.00 12/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989988
Principal investigator 1 ModernaTX, Inc. $33.75 12/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990018
Principal investigator 1 ModernaTX, Inc. $11,609.95 12/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001635
Principal investigator 1 ModernaTX, Inc. $5,475.80 12/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001697
Principal investigator 1 PFIZER INC. $2,348.50 12/17/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228732758
Principal investigator 1 ModernaTX, Inc. $303.75 12/15/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989946
Principal investigator 1 ModernaTX, Inc. $263.25 12/15/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990032
Principal investigator 1 Amgen Inc. $4,546.92 12/12/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2) No dispute reported 06/30/2026 1246646420
Principal investigator 1 Amgen Inc. $19,993.92 12/12/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity No dispute reported 06/30/2026 1246646424
Principal investigator 1 SANOFI US SERVICES INC. $6,132.00 12/05/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.06 12/04/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184269461
Principal investigator 1 ModernaTX, Inc. $445.50 12/03/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989984
Principal investigator 1 ModernaTX, Inc. $101.25 12/03/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990010
Principal investigator 1 PFIZER INC. $587.50 12/02/2025 Non-covered Recipient Entity
Peninsula Research Associates
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228718658
Principal investigator 1 ModernaTX, Inc. $4,779.02 12/01/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989936
Principal investigator 1 ModernaTX, Inc. $27,043.92 12/01/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989940
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 12/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347891
Principal investigator 1 ModernaTX, Inc. $322.05 11/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001633
Principal investigator 1 ModernaTX, Inc. $5,977.40 11/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001687
Principal investigator 1 ModernaTX, Inc. $41,162.55 11/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001709
Principal investigator 1 PFIZER INC. $20,850.00 11/27/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228724562
Principal investigator 1 PFIZER INC. $5,721.40 11/26/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228738516
Principal investigator 1 SANOFI PASTEUR INC. $223.00 11/25/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116029
Principal investigator 1 SANOFI PASTEUR INC. $16,834.50 11/17/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116019
Principal investigator 1 PFIZER INC. $221.58 11/13/2025 Non-covered Recipient Entity
Peninsula Research Associates
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228720053
Principal investigator 1 PFIZER INC. $272.70 11/13/2025 Non-covered Recipient Entity
Peninsula Research Associates
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228728251
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/12/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120932
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/12/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120945
Principal investigator 1 ModernaTX, Inc. $820.12 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989948
Principal investigator 1 ModernaTX, Inc. $2,056.56 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989954
Principal investigator 1 ModernaTX, Inc. $13,104.30 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989958
Principal investigator 1 ModernaTX, Inc. $7,267.54 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989960
Principal investigator 1 ModernaTX, Inc. $1,997.52 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989996
Principal investigator 1 ModernaTX, Inc. $2,416.95 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989998
Principal investigator 1 ModernaTX, Inc. $7,541.71 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990000
Principal investigator 1 ModernaTX, Inc. $5,723.02 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990022
Principal investigator 1 ModernaTX, Inc. $138.10 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990026
Principal investigator 1 ModernaTX, Inc. $14,057.20 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990030
Principal investigator 1 ModernaTX, Inc. $14,442.50 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990036
Principal investigator 1 ModernaTX, Inc. $4,900.80 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990050
Principal investigator 1 ModernaTX, Inc. $14,337.75 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990058
Principal investigator 1 ModernaTX, Inc. $6,173.30 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990060
Principal investigator 1 ModernaTX, Inc. $5,955.95 11/10/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990062
Principal investigator 1 GlaxoSmithKline, LLC. $3,805.00 11/05/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120971
Principal investigator 1 PFIZER INC. $6,260.10 11/05/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228728794
Principal investigator 1 Eli Lilly and Company $16,000.40 11/04/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 52-WEEK STUDY, TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA No dispute reported 06/30/2026 1187888676
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 11/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347877
Principal investigator 1 ModernaTX, Inc. $1,750.00 10/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990024
Principal investigator 1 ModernaTX, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990028
Principal investigator 1 ModernaTX, Inc. $2,500.00 10/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990052
Principal investigator 1 ModernaTX, Inc. $894.00 10/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990054
Principal investigator 1 PFIZER INC. $2,348.50 10/29/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759371
Principal investigator 1 ModernaTX, Inc. $4,186.65 10/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001647
Principal investigator 1 ModernaTX, Inc. $6,165.50 10/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001675
Principal investigator 1 ModernaTX, Inc. $500.00 10/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989944
Principal investigator 1 ModernaTX, Inc. $600.00 10/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990002
Principal investigator 1 ModernaTX, Inc. $67.50 10/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $906.88 10/23/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252800
Principal investigator 1 SANOFI PASTEUR INC. $23,753.25 10/23/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116025
Principal investigator 1 AstraZeneca Pharmaceuticals LP $308,890.30 10/22/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA No dispute reported 06/30/2026 1185552823
Principal investigator 1 ModernaTX, Inc. $500.00 10/22/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989994
Principal investigator 1 SANOFI PASTEUR INC. $66,865.50 10/10/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116014
Principal investigator 1 SANOFI US SERVICES INC. $21,882.00 10/10/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,457.41 10/03/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244815
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 10/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347783
Principal investigator 1 ModernaTX, Inc. $5,872.90 09/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001663
Principal investigator 1 ModernaTX, Inc. $4,508.70 09/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001701
Principal investigator 1 PFIZER INC. $3,911.60 09/26/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751835
Principal investigator 1 Incyte Corporation $1,575.00 09/23/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES PRA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576483
Principal investigator 1 Incyte Corporation $2,174.00 09/23/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES PRA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576489
Principal investigator 1 Incyte Corporation $18,000.00 09/23/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES PRA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576500
Principal investigator 1 Incyte Corporation $5,000.00 09/12/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES PRA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576495
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 09/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347747
Principal investigator 1 ModernaTX, Inc. $1,055.45 08/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001661
Principal investigator 1 ModernaTX, Inc. $6,228.20 08/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001685
Principal investigator 1 ModernaTX, Inc. $14,814.30 08/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001711
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $9,250.00 08/27/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347412
Principal investigator 1 PFIZER INC. $18,935.50 08/23/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228767082
Principal investigator 1 ModernaTX, Inc. $51,991.92 08/22/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989986
Principal investigator 1 GlaxoSmithKline, LLC. $20.00 08/20/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120965
Principal investigator 1 Eli Lilly and Company $133,221.07 08/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 No dispute reported 06/30/2026 1187887606
Principal investigator 1 ModernaTX, Inc. $325.00 08/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012294
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 08/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347871
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $149.10 07/30/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347827
Principal investigator 1 PFIZER INC. $13,503.00 07/29/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772701
Principal investigator 1 ModernaTX, Inc. $1,588.40 07/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001683
Principal investigator 1 ModernaTX, Inc. $5,277.25 07/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001713
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $1,050.00 07/24/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347949
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $820.05 07/22/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347739
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $260.40 07/22/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347867
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $60.90 07/18/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347713
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $0.11 07/18/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.08 07/17/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,122.71 07/17/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.08 07/17/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.12 07/17/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217254
Principal investigator 1 ModernaTX, Inc. $60,453.00 07/09/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989992
Principal investigator 1 ModernaTX, Inc. $264.00 07/09/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002589
Principal investigator 1 PFIZER INC. $18,774.70 07/02/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773483
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 07/01/2025 Non-covered Recipient Entity
PENINSULA RESEARCH ASSOCIATES
RD006866 No dispute reported 06/30/2026 1244347719
Principal investigator 1 ModernaTX, Inc. $322.05 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001649
Principal investigator 1 ModernaTX, Inc. $12,665.40 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001659
Principal investigator 1 ModernaTX, Inc. $5,099.60 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001707
Principal investigator 1 ModernaTX, Inc. $7,224.75 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002583
Principal investigator 1 ModernaTX, Inc. $94,824.40 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012302
Principal investigator 1 ModernaTX, Inc. $23,672.48 06/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012322
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,750.00 06/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185552825
Principal investigator 1 ModernaTX, Inc. $325.00 06/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012306
Principal investigator 1 ModernaTX, Inc. $264.00 06/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012332
Principal investigator 1 SANOFI US SERVICES INC. $10,224.20 06/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150354
Principal investigator 1 ModernaTX, Inc. $8,695.35 06/18/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001693
Principal investigator 1 ModernaTX, Inc. $17,942.65 06/18/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001705
Principal investigator 1 ModernaTX, Inc. $5,768.40 06/18/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001715
Principal investigator 1 SANOFI PASTEUR INC. $377,512.52 06/17/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115978
Principal investigator 1 ModernaTX, Inc. $2,516.00 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989980
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989982
Principal investigator 1 ModernaTX, Inc. $2,644.00 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989990
Principal investigator 1 ModernaTX, Inc. $500.00 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990014
Principal investigator 1 ModernaTX, Inc. $500.00 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990046
Principal investigator 1 ModernaTX, Inc. $33.75 06/06/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990048
Principal investigator 1 ModernaTX, Inc. $750.00 06/04/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989952
Principal investigator 1 ModernaTX, Inc. $500.00 06/04/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990016
Principal investigator 1 SANOFI PASTEUR INC. $96,880.05 06/02/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115971
Principal investigator 1 SANOFI US SERVICES INC. $2,842.00 06/02/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150347
Principal investigator 1 ModernaTX, Inc. $675.00 05/30/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012316
Principal investigator 1 PFIZER INC. $17,025.40 05/30/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773636
Principal investigator 1 ModernaTX, Inc. $125.00 05/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989956
Principal investigator 1 ModernaTX, Inc. $500.00 05/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990056
Principal investigator 1 ModernaTX, Inc. $44,328.90 05/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001639
Principal investigator 1 ModernaTX, Inc. $9,983.55 05/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001667
Principal investigator 1 ModernaTX, Inc. $6,416.30 05/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001703
Principal investigator 1 SANOFI US SERVICES INC. $392.00 05/22/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150637
Principal investigator 1 SANOFI US SERVICES INC. $392.00 05/22/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150645
Principal investigator 1 SANOFI US SERVICES INC. $98.00 05/22/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150653
Principal investigator 1 SANOFI PASTEUR INC. $13,615.00 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115910
Principal investigator 1 SANOFI PASTEUR INC. $21,784.00 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115916
Principal investigator 1 SANOFI PASTEUR INC. $1,758.40 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115922
Principal investigator 1 SANOFI PASTEUR INC. $439.60 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115926
Principal investigator 1 SANOFI PASTEUR INC. $1,318.80 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115931
Principal investigator 1 SANOFI PASTEUR INC. $879.20 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115935
Principal investigator 1 SANOFI PASTEUR INC. $879.20 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115940
Principal investigator 1 SANOFI PASTEUR INC. $879.20 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115945
Principal investigator 1 SANOFI PASTEUR INC. $750.00 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115951
Principal investigator 1 SANOFI US SERVICES INC. $3,724.00 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150628
Principal investigator 1 SANOFI US SERVICES INC. $882.00 05/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150634
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115872
Principal investigator 1 SANOFI PASTEUR INC. $10,046.40 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115886
Principal investigator 1 SANOFI PASTEUR INC. $5,940.00 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115892
Principal investigator 1 SANOFI PASTEUR INC. $10,883.60 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115898
Principal investigator 1 SANOFI PASTEUR INC. $279.45 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115904
Principal investigator 1 SANOFI PASTEUR INC. $606.06 05/20/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116008
Principal investigator 1 PFIZER INC. $23,728.15 05/14/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766841
Principal investigator 1 PFIZER INC. $907.20 05/10/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228776156
Principal investigator 1 SANOFI US SERVICES INC. $17,192.00 05/09/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150622
Principal investigator 1 Eli Lilly and Company $895.23 05/08/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888130
Principal investigator 1 ModernaTX, Inc. $33.75 05/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989938
Principal investigator 1 ModernaTX, Inc. $33.75 05/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989978
Principal investigator 1 ModernaTX, Inc. $33.75 05/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990008
Principal investigator 1 PFIZER INC. $488.60 05/06/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781742
Principal investigator 1 Eli Lilly and Company $4,375.00 05/05/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885628
Principal investigator 1 PFIZER INC. $8,098.30 05/03/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773646
Principal investigator 1 ModernaTX, Inc. $250.00 05/02/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012312
Principal investigator 1 ModernaTX, Inc. $450.00 05/02/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012328
Principal investigator 1 Eli Lilly and Company $139.18 04/30/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187888940
Principal investigator 1 PFIZER INC. $495.60 04/29/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228778880
Principal investigator 1 ModernaTX, Inc. $5,956.50 04/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001655
Principal investigator 1 ModernaTX, Inc. $26,408.10 04/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001677
Principal investigator 1 ModernaTX, Inc. $87,694.88 04/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002585
Principal investigator 1 ModernaTX, Inc. $54,908.10 04/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012324
Principal investigator 1 ModernaTX, Inc. $91,807.26 04/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012326
Principal investigator 1 SANOFI PASTEUR INC. $4,082.40 04/28/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115964
Principal investigator 1 ModernaTX, Inc. $58,441.51 04/23/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989942
Principal investigator 1 ModernaTX, Inc. $1,750.00 04/23/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989974
Principal investigator 1 ModernaTX, Inc. $1,750.00 04/23/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990012
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252990044
Principal investigator 1 SANOFI PASTEUR INC. $13,583.70 04/16/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226116005
Principal investigator 1 PFIZER INC. $5,600.00 04/15/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228791558
Principal investigator 1 ModernaTX, Inc. $22,499.10 04/09/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012300
Principal investigator 1 PFIZER INC. $10,709.40 04/09/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228778753
Principal investigator 1 Eli Lilly and Company $2,722.60 04/08/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187885626
Principal investigator 1 Eli Lilly and Company $924.70 04/08/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888674
Principal investigator 1 Eli Lilly and Company $2,710.65 04/08/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890124
Principal investigator 1 Eli Lilly and Company $2,524.12 04/08/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187890440
Principal investigator 1 SANOFI PASTEUR INC. $810.00 04/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115988
Principal investigator 1 SANOFI PASTEUR INC. $152.55 04/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115995
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 04/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115999
Principal investigator 1 ModernaTX, Inc. $200.00 04/01/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012330
Principal investigator 1 SANOFI PASTEUR INC. $527.85 04/01/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115983
Principal investigator 1 PFIZER INC. $10,249.80 03/29/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228788019
Principal investigator 1 SANOFI US SERVICES INC. $18,135.60 03/28/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150401
Principal investigator 1 SANOFI PASTEUR INC. $13,750.00 03/27/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115852
Principal investigator 1 SANOFI PASTEUR INC. $191.70 03/27/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115858
Principal investigator 1 SANOFI PASTEUR INC. $184,796.10 03/26/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115845
Principal investigator 1 ModernaTX, Inc. $325.00 03/25/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002587
Principal investigator 1 SANOFI US SERVICES INC. $121,400.30 03/25/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150379
Principal investigator 1 ModernaTX, Inc. $686.85 03/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001643
Principal investigator 1 ModernaTX, Inc. $6,144.60 03/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001651
Principal investigator 1 ModernaTX, Inc. $20,611.20 03/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001671
Principal investigator 1 ModernaTX, Inc. $4,221.80 03/24/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001699
Principal investigator 1 SANOFI US SERVICES INC. $51,585.80 03/21/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.02 03/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,652.47 03/11/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184170766
Principal investigator 1 PFIZER INC. $9,293.10 03/04/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228780209
Principal investigator 1 SANOFI US SERVICES INC. $78,678.60 03/04/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150368
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/03/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192114647
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 03/03/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120939
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/03/2025 Non-covered Recipient Entity
HEADLANDS HORIZONS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192120951
Principal investigator 1 SANOFI PASTEUR INC. $1,670.20 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115775
Principal investigator 1 SANOFI PASTEUR INC. $22,612.80 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115783
Principal investigator 1 SANOFI PASTEUR INC. $2,826.60 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115790
Principal investigator 1 SANOFI PASTEUR INC. $500.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115793
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115800
Principal investigator 1 SANOFI PASTEUR INC. $960.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115806
Principal investigator 1 SANOFI PASTEUR INC. $250.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115811
Principal investigator 1 SANOFI PASTEUR INC. $879.20 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115814
Principal investigator 1 SANOFI PASTEUR INC. $500.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115820
Principal investigator 1 SANOFI PASTEUR INC. $1,670.20 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115827
Principal investigator 1 SANOFI PASTEUR INC. $950.00 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115834
Principal investigator 1 SANOFI PASTEUR INC. $477,269.55 03/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115839
Principal investigator 1 ModernaTX, Inc. $15,249.00 02/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012304
Principal investigator 1 ModernaTX, Inc. $264.00 02/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012314
Principal investigator 1 ModernaTX, Inc. $557.70 02/28/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012318
Principal investigator 1 ModernaTX, Inc. $1,581.32 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252989950
Principal investigator 1 ModernaTX, Inc. $20,933.25 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001637
Principal investigator 1 ModernaTX, Inc. $1,630.20 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001645
Principal investigator 1 ModernaTX, Inc. $21,109.00 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001657
Principal investigator 1 ModernaTX, Inc. $6,646.20 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001665
Principal investigator 1 ModernaTX, Inc. $16,777.00 02/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001669
Principal investigator 1 ModernaTX, Inc. $625.00 02/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989964
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989970
Principal investigator 1 ModernaTX, Inc. $1,746.00 02/26/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990042
Principal investigator 1 Eli Lilly and Company $79,513.00 02/25/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187888672
Principal investigator 1 ModernaTX, Inc. $22,034.38 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989932
Principal investigator 1 ModernaTX, Inc. $1,400.00 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989934
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989966
Principal investigator 1 ModernaTX, Inc. $23,603.28 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989972
Principal investigator 1 ModernaTX, Inc. $1,626.00 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990004
Principal investigator 1 ModernaTX, Inc. $2,153.25 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990006
Principal investigator 1 ModernaTX, Inc. $1,329.75 02/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990040
Principal investigator 1 ModernaTX, Inc. $5,000.00 02/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989968
Principal investigator 1 ModernaTX, Inc. $1,000.00 02/19/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990038
Principal investigator 1 ModernaTX, Inc. $3,355.40 02/17/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001673
Principal investigator 1 Eli Lilly and Company $487,121.01 02/11/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187888670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,984.80 02/11/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184153052
Principal investigator 1 SANOFI PASTEUR INC. $257,314.47 02/11/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115879
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150574
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150580
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150589
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150597
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150604
Principal investigator 1 SANOFI US SERVICES INC. $2,058.00 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150610
Principal investigator 1 SANOFI US SERVICES INC. $13,204.80 02/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150616
Principal investigator 1 SANOFI US SERVICES INC. $825.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150390
Principal investigator 1 SANOFI US SERVICES INC. $686.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150394
Principal investigator 1 SANOFI US SERVICES INC. $495.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150406
Principal investigator 1 SANOFI US SERVICES INC. $392.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150413
Principal investigator 1 SANOFI US SERVICES INC. $495.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150419
Principal investigator 1 SANOFI US SERVICES INC. $630.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150424
Principal investigator 1 SANOFI US SERVICES INC. $350.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150429
Principal investigator 1 SANOFI US SERVICES INC. $420.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150434
Principal investigator 1 SANOFI US SERVICES INC. $224.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150442
Principal investigator 1 SANOFI US SERVICES INC. $106.40 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150447
Principal investigator 1 SANOFI US SERVICES INC. $231.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150454
Principal investigator 1 SANOFI US SERVICES INC. $98.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150461
Principal investigator 1 SANOFI US SERVICES INC. $2,254.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150467
Principal investigator 1 SANOFI US SERVICES INC. $98.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150475
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150486
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150491
Principal investigator 1 SANOFI US SERVICES INC. $686.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150498
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150503
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150509
Principal investigator 1 SANOFI US SERVICES INC. $392.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150517
Principal investigator 1 SANOFI US SERVICES INC. $1,666.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150523
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150529
Principal investigator 1 SANOFI US SERVICES INC. $686.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150537
Principal investigator 1 SANOFI US SERVICES INC. $490.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150547
Principal investigator 1 SANOFI US SERVICES INC. $588.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150552
Principal investigator 1 SANOFI US SERVICES INC. $196.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150557
Principal investigator 1 SANOFI US SERVICES INC. $2,450.00 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150561
Principal investigator 1 SANOFI US SERVICES INC. $59,322.20 02/06/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150569
Principal investigator 1 ModernaTX, Inc. $11,069.24 02/05/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252990034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.30 02/05/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184152516
Principal investigator 1 Eli Lilly and Company $90.00 01/31/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187885262
Principal investigator 1 Eli Lilly and Company $4,048.73 01/31/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888318
Principal investigator 1 AstraZeneca Pharmaceuticals LP $90,400.80 01/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C No dispute reported 06/30/2026 1185552821
Principal investigator 1 ModernaTX, Inc. $767.57 01/29/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252989962
Principal investigator 1 ModernaTX, Inc. $6,332.70 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001631
Principal investigator 1 ModernaTX, Inc. $36,909.40 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001641
Principal investigator 1 ModernaTX, Inc. $3,636.60 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001679
Principal investigator 1 ModernaTX, Inc. $3,302.20 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001689
Principal investigator 1 ModernaTX, Inc. $17,068.65 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001695
Principal investigator 1 ModernaTX, Inc. $27,454.05 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012298
Principal investigator 1 ModernaTX, Inc. $5,075.85 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012308
Principal investigator 1 ModernaTX, Inc. $19,720.48 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012310
Principal investigator 1 ModernaTX, Inc. $40,084.86 01/27/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012320
Principal investigator 1 SANOFI PASTEUR INC. $2,486.35 01/27/2025 Non-covered Recipient Entity
Peninsula Research Associates
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older No dispute reported 06/30/2026 1226116376
Principal investigator 1 ModernaTX, Inc. $10,800.00 01/22/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001653
Principal investigator 1 Eli Lilly and Company $87,573.00 01/21/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885624
Principal investigator 1 Eli Lilly and Company $1,668.18 01/21/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187889764
Principal investigator 1 SANOFI PASTEUR INC. $500.00 01/20/2025 Non-covered Recipient Entity
Peninsula Research Associates,inc
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older No dispute reported 06/30/2026 1226113997
Principal investigator 1 SANOFI PASTEUR INC. $500.00 01/20/2025 Non-covered Recipient Entity
Peninsula Research Associates,inc
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older No dispute reported 06/30/2026 1226114002
Principal investigator 1 SANOFI PASTEUR INC. $500.00 01/20/2025 Non-covered Recipient Entity
Peninsula Research Associates
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older No dispute reported 06/30/2026 1226116372
Principal investigator 1 AstraZeneca Pharmaceuticals LP $95,423.75 01/16/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A randomized, modified double-blind, active controlled study to characterize the immunogenicity and safety of IVX-A12 No dispute reported 06/30/2026 1185552819
Principal investigator 1 SANOFI PASTEUR INC. $500.00 01/16/2025 Non-covered Recipient Entity
Peninsula Research Associates,inc
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older No dispute reported 06/30/2026 1226113991
Principal investigator 1 PFIZER INC. $8,118.60 01/15/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228798472
Principal investigator 1 PFIZER INC. $3,585.00 01/15/2025 Non-covered Recipient Entity
Peninsula Headlands LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228799309
Principal investigator 1 ModernaTX, Inc. $199.56 01/13/2025 Non-covered Recipient Entity
Peninsula Research Associates
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001691
Principal investigator 1 Eli Lilly and Company $6,510.55 01/09/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187885264
Principal investigator 1 Eli Lilly and Company $3,084.09 01/09/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885266
Principal investigator 1 Eli Lilly and Company $9,079.66 01/09/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187887494
Principal investigator 1 Eli Lilly and Company $688.27 01/09/2025 Non-covered Recipient Entity
PALOS VERDES MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888932
Principal investigator 1 ModernaTX, Inc. $68.30 01/08/2025 Non-covered Recipient Entity
Peninsula Research Associates
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001681
Principal investigator 1 Eli Lilly and Company $200,272.00 01/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187887604
Principal investigator 1 Eli Lilly and Company $83,642.00 01/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888938
Principal investigator 1 Eli Lilly and Company $327,825.00 01/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187888942
Principal investigator 1 Eli Lilly and Company $217,429.00 01/07/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187890122
Principal investigator 1 SANOFI PASTEUR INC. $173,889.06 01/07/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226115864
Principal investigator 1 ModernaTX, Inc. $3,408.78 01/03/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252989976
Principal investigator 1 ModernaTX, Inc. $8,800.00 01/03/2025 Non-covered Recipient Entity
PENINSULA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012296
Principal investigator 1 SANOFI US SERVICES INC. $8,184.40 01/03/2025 Non-covered Recipient Entity
Peninsula Headlands Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226150385